Abstract:To assess the chronological participation of sclerostin and FGF23 in bone metabolism, this study tracked the immunolocalization of sclerostin and FGF23 in the metaphyses of murine long bones from embryonic day 18 (E18) through 1 day after birth, 1 week, 2 weeks, 4 weeks, 8 weeks, and 20 weeks of age. We have selected two regions in the metaphyseal trabeculae for assessing sclerostin and FGF23 localization: close to the chondro-osseous junction, i.e., bone modeling site even in the adult animals, and the trabec… Show more
“…In this study, the micro-circumstance of the metastasized lesion might have been able to induce MDA-MB-231 to secrete FGF23. In our previous report, the embryonic and infant stages of bone expressed abundant FGFR1 and klotho, and FGF23 was produced mainly by osteoblastic cells rather than osteocytes in the embryonic stage [16]. However, as mice grow, FGF23synthesizing cells were seen to chronologically shift from osteoblastic cells to osteocytes.…”
Section: Discussionmentioning
confidence: 82%
“…All animal experiments were conducted under the Guidelines for Animal Experimentation of Hokkaido University (Approval No. [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31]. Human breast carcinoma MDA-MB-231 cells (American Type Culture Collection, Rockville, MD)…”
Section: Tissue Preparation For Histological Examinationmentioning
confidence: 99%
“…To evaluate the mRNAs encoding Fgf23, Fgfr1, Klotho, and Gapdh, total RNA was extracted from the femora of control mice, the femora of mice metastasized with MDA-MB-231 cells, the mammary glands of control mice, and mammary glands injected with MDA-MB-231 cells, as previously reported [16]. In brief, the metastasized femora were sagitally cut, and the bone-metastasized tumor nests inside the femora were confirmed under a binocular microscope and then extracted from the femora.…”
Section: Rt-pcr and Real-time Pcr For The Expression Of Fgf 23 Fgfr1 ...mentioning
confidence: 99%
“…In a normal state, FGF23 is mainly synthesized by osteocytes in adults [15,16] and is circulated to reach the kidney.…”
After the onset of bone metastasis, tumor cells appear to modify surrounding microenvironments for their benefit, and particularly, the levels of circulating fibroblast growth factor (FGF) 23 in patients with tumors has been highlighted. Herein, we have attempted to verify if human breast carcinoma MDA-MB-231 cells metastasized in the long bone of nu/nu mice would synthesize FGF23. Serum concentrations of calcium, phosphate (Pi) and FGF23 were measured in control nu/nu mice, bone-metastasized mice, and mice with mammary gland injected with MDA-MB-231 cells mimicking primary mammary tumors. Consequently, MDA-MB-231 cells revealed intense FGF23 reactivity in metastasized lesions, whereas MDA-MB-231 cells cultured in vitro or when injected into the mammary glands (without bone metastasis) showed weak FGF23 immunoreactivity. Although the bone-metastasized MDA-MB-231 cells abundantly synthesized FGF23, osteocytes adjacent to the FGF23-immunopositive tumors, unlike intact osteocytes, showed no FGF23. Despite significantly elevated serum FGF23 levels in bone-metastasized mice, there was no significant decrease in the serum Pi concentration when compared with the intact mice and mice with a mass of MDA-MB-231 cells in mammary glands. The metastasized femora showed increased expression and FGFR1 immunoreactivity in fibroblastic stromal cells, whereas femora of control mice showed no obvious FGFR1 immunoreactivity. Taken together, it seems likely that MDA-MB-231 cells synthesize FGF23 when metastasized to a bone, and thus affect FGFR1-positive stromal cells in the metastasized tumor nest in a paracrine manner.
“…In this study, the micro-circumstance of the metastasized lesion might have been able to induce MDA-MB-231 to secrete FGF23. In our previous report, the embryonic and infant stages of bone expressed abundant FGFR1 and klotho, and FGF23 was produced mainly by osteoblastic cells rather than osteocytes in the embryonic stage [16]. However, as mice grow, FGF23synthesizing cells were seen to chronologically shift from osteoblastic cells to osteocytes.…”
Section: Discussionmentioning
confidence: 82%
“…All animal experiments were conducted under the Guidelines for Animal Experimentation of Hokkaido University (Approval No. [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31]. Human breast carcinoma MDA-MB-231 cells (American Type Culture Collection, Rockville, MD)…”
Section: Tissue Preparation For Histological Examinationmentioning
confidence: 99%
“…To evaluate the mRNAs encoding Fgf23, Fgfr1, Klotho, and Gapdh, total RNA was extracted from the femora of control mice, the femora of mice metastasized with MDA-MB-231 cells, the mammary glands of control mice, and mammary glands injected with MDA-MB-231 cells, as previously reported [16]. In brief, the metastasized femora were sagitally cut, and the bone-metastasized tumor nests inside the femora were confirmed under a binocular microscope and then extracted from the femora.…”
Section: Rt-pcr and Real-time Pcr For The Expression Of Fgf 23 Fgfr1 ...mentioning
confidence: 99%
“…In a normal state, FGF23 is mainly synthesized by osteocytes in adults [15,16] and is circulated to reach the kidney.…”
After the onset of bone metastasis, tumor cells appear to modify surrounding microenvironments for their benefit, and particularly, the levels of circulating fibroblast growth factor (FGF) 23 in patients with tumors has been highlighted. Herein, we have attempted to verify if human breast carcinoma MDA-MB-231 cells metastasized in the long bone of nu/nu mice would synthesize FGF23. Serum concentrations of calcium, phosphate (Pi) and FGF23 were measured in control nu/nu mice, bone-metastasized mice, and mice with mammary gland injected with MDA-MB-231 cells mimicking primary mammary tumors. Consequently, MDA-MB-231 cells revealed intense FGF23 reactivity in metastasized lesions, whereas MDA-MB-231 cells cultured in vitro or when injected into the mammary glands (without bone metastasis) showed weak FGF23 immunoreactivity. Although the bone-metastasized MDA-MB-231 cells abundantly synthesized FGF23, osteocytes adjacent to the FGF23-immunopositive tumors, unlike intact osteocytes, showed no FGF23. Despite significantly elevated serum FGF23 levels in bone-metastasized mice, there was no significant decrease in the serum Pi concentration when compared with the intact mice and mice with a mass of MDA-MB-231 cells in mammary glands. The metastasized femora showed increased expression and FGFR1 immunoreactivity in fibroblastic stromal cells, whereas femora of control mice showed no obvious FGFR1 immunoreactivity. Taken together, it seems likely that MDA-MB-231 cells synthesize FGF23 when metastasized to a bone, and thus affect FGFR1-positive stromal cells in the metastasized tumor nest in a paracrine manner.
“…However, recent studies have proposed an autocrine function of FGF23, which, at least in part, is related to bone mineralization. Osteoblasts/osteocytes express not only FGF23 but also the FGFR1c/αklotho receptor complex [ 27 , 28 ], consequently regulating bone mineralization in an autocrine manner [ 29 ]. In addition, PHEX has been postulated to bind the small integrin-binding ligand N-linked glycoprotein (SIBLING) family including osteopontin, matrix extracellular phosphoglycoprotein (MEPE), dentin matrix protein 1 (DMP1), dentin sialoprotein, and bone sialoprotein for the local regulation of mineralization in bone [ 30 , 31 , 32 , 33 , 34 , 35 ].…”
The present study aimed to demonstrate the immunolocalization and/or gene expressions of the enzymes and membrane transporters involved in bone mineralization after the intermittent administration of parathyroid hormone (PTH). The study especially focused on TNALP, ENPP1, and PHOSPHO1, which are involved in matrix vesicle-mediated mineralization, as well as PHEX and the SIBLING family, which regulate mineralization deep inside bone. Six-week-old male mice were subcutaneously injected with 20 μg/kg/day of human PTH (1–34) two times per day (n = 6) or four times per day (n = 6) for two weeks. Additionally, control mice (n = 6) received a vehicle. Consistently with an increase in the volume of the femoral trabeculae, the mineral appositional rate increased after PTH administration. The areas positive for PHOSPHO1, TNALP, and ENPP1 in the femoral metaphyses expanded, and the gene expressions assessed by real-time PCR were elevated in PTH-administered specimens when compared with the findings in control specimens. The immunoreactivity and/or gene expressions of PHEX and the SIBLING family (MEPE, osteopontin, and DMP1) significantly increased after PTH administration. For example, MEPE immunoreactivity was evident in some osteocytes in PTH-administered specimens but was hardly observed in control specimens. In contrast, mRNA encoding cathepsin B was significantly reduced. Therefore, the bone matrix deep inside might be further mineralized by PHEX/SIBLING family after PTH administration. In summary, it is likely that PTH accelerates mineralization to maintain a balance with elevated matrix synthesis, presumably by mediating TNALP/ENPP1 cooperation and stimulating PHEX/SIBLING family expression.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.